Oppenheimer raises Kymera Therapeutics stock price target ahead of Phase 1b readout
PositiveFinancial Markets
Oppenheimer raises Kymera Therapeutics stock price target ahead of Phase 1b readout
Oppenheimer has raised the stock price target for Kymera Therapeutics as anticipation builds for the upcoming Phase 1b readout. This positive adjustment reflects confidence in the company's potential and the promising developments in their clinical trials.
— via World Pulse Now AI Editorial System





